登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 重要风险提示： 1、潜江永安药业股份有限公司（以下简称"公司"，证券简称：永安药业，证券代码：002365）股票交 易于2025年5月15日至2025年5月28日连续十个交易日内收盘价格涨幅偏离值累计超过100%，根据深圳 证券交易所的有关规定，属于股票交易严重异常波动情形。 2、近期公司股价短期涨幅较大，已严重偏离公司基本面，存在较高的炒作风险。公司不存在应披露未 披露的重大信息。2025年一季度，公司处于亏损状态。公司特别提醒投资者，注意投资风险，理性决 策，审慎投资。 3、截至本公告披露时，中证指数有限公司的最新数据显示，公司的静态市盈率为106.82，滚动市盈率 为229.74，市净率为3.34；公司所属中上协行业分类"医药制造业"的静态市盈率为28.22，滚动市盈率为 27.74，市净率为2.72。公司静态市盈率、滚动市盈率、市净率均高于公司所属中上协行业分类"医药制 造业"水平。公司已连续多日发布股票交易异常波动公告，特别提醒广大投资者注意二级市场交易 ...

Group 1 - China Energy Engineering announced that its subsidiary, China Power Engineering Consulting Group Northwest Electric Power Design Institute, has won a bid for a coal power project with a contract value of approximately 14.586 billion yuan [1] - Hehe Information plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its global strategy and brand recognition [2] - Jiaying Pharmaceutical is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws [3] Group 2 - Longgao Co. received notice of a restructuring involving its controlling shareholder, Longyan Investment Development Group, which will become a wholly-owned subsidiary of the newly established Longyan Investment Development Group with a registered capital of 3 billion yuan [4] - Fuda Co. signed an investment agreement to build a precision gear project for electric drive systems and robotic transmission components in Pinghu Economic and Technological Development Zone, covering an area of approximately 132 acres [5] - ST United plans to acquire 100% equity of Jiangxi Runtian Industrial Co., Ltd. through a combination of share issuance and cash payment, with the stock resuming trading on May 29, 2025 [6] Group 3 - ST Huaxi signed a significant contract worth approximately 2.084 billion yuan for the repair and installation of a thermal power plant in Iraq, which represents about 80.38% of its latest audited revenue [7] - ST Longjin's stock will enter a delisting arrangement period starting June 6, 2025, following a decision by the Shenzhen Stock Exchange to terminate its listing [8][9] - ST Jiyuan's stock is set to be delisted on May 29, 2025, due to triggering mandatory delisting conditions without entering a delisting arrangement period [10]

Market Overview - The A-share market experienced a five-day decline across major indices, with a total trading volume of 1.03 trillion yuan and nearly 3,500 stocks rising [1] - Market focus shifted towards nuclear power, controllable nuclear fusion, and dairy sectors, while the fertilizer sector saw a decline [1] Stock Performance - A total of 57 stocks hit the daily limit up, with 17 stocks achieving consecutive limit ups, and a limit up rate of 71% (excluding ST and delisted stocks) [3] - Notable performers included Yong'an Pharmaceutical, which achieved 7 limit ups in 11 days, and Binhai Energy with 6 limit ups in 8 days [3] Key Stocks and Their Movements - **Yong'an Pharmaceutical**: Price increased by 10.00% to 24.63 yuan, with a trading volume of 20.52 billion yuan and a turnover rate of 34.68% [15][16] - **Youfu Co., Ltd.**: Price rose by 9.98% to 10.69 yuan, with a trading volume of 22.33 billion yuan and a turnover rate of 21.46% [13][14] - **Shangwei Co., Ltd.**: Price increased by 9.96% to 9.05 yuan, with a trading volume of 14.65 billion yuan and a turnover rate of 26.49% [4] Sector Highlights - The nuclear power sector saw significant interest, with stocks like Shangwei Co., Ltd. and Rongfa Nuclear Power achieving multiple limit ups due to positive market sentiment around nuclear energy [4][10] - The fertilizer and chemical sectors faced downward pressure following an explosion incident at a chemical plant, which affected market sentiment [17] Institutional and Retail Investor Activity - The top net purchases on the trading board were from Snowman Co., Ltd., Youfu Co., Ltd., and Yong'an Pharmaceutical, with net purchases of 175 million yuan, 161 million yuan, and 92.96 million yuan respectively [6] - Conversely, the top net sales were from Guangju Energy, Suzhou Longjie, and Zhongqi Co., Ltd., with net sales of 110 million yuan, 106 million yuan, and 98.75 million yuan respectively [7] Notable News and Developments - Yong'an Pharmaceutical announced a significant increase in its sales volume for 2024, projected to reach 49,700 tons, a year-on-year increase of 16.32% [15] - The controllable nuclear fusion sector is gaining traction, with reports indicating that 26 out of 37 surveyed companies believe the first nuclear fusion unit will be operational by 2035 [9]

智通财经5月28日电，永安药业(002365.SZ)公告称，公司股票交易于2025年5月15日至5月28日连续十个 交易日内收盘价格涨幅偏离值累计超过100%，属于股票交易严重异常波动情形。近期公司股价短期涨 幅较大，已严重偏离公司基本面，存在较高的炒作风险。公司不存在应披露未披露的重大信息。2025年 一季度，公司处于亏损状态。公司特别提醒投资者，注意投资风险，理性决策，审慎投资。 11天7板永安药业：近期公司股价短期涨幅较大 存在较高的炒作风险 ...

证券代码：002365 证券简称：永安药业 公告编号：2025-37 潜江永安药业股份有限公司 关于股票交易严重异常波动暨风险提示公告 （一）经核查，公司前期披露的信息不存在需要更正、补充之处。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要风险提示： 1、潜江永安药业股份有限公司（以下简称"公司"，证券简称：永安药业， 证券代码：002365）股票交易于 2025 年 5 月 15 日至 2025 年 5 月 28 日连续十个 交易日内收盘价格涨幅偏离值累计超过 100%，根据深圳证券交易所的有关规定， 属于股票交易严重异常波动情形。 2、近期公司股价短期涨幅较大，已严重偏离公司基本面，存在较高的炒作 风险。公司不存在应披露未披露的重大信息。2025 年一季度，公司处于亏损状 态。公司特别提醒投资者，注意投资风险，理性决策，审慎投资。 3、截至本公告披露时，中证指数有限公司的最新数据显示，公司的静态市 盈率为 106.82，滚动市盈率为 229.74，市净率为 3.34；公司所属中上协行业分 类"医药制造业"的静态市盈率为 28.22，滚动市盈率为 2 ...

Core Viewpoint - Yong'an Pharmaceutical (002365) has experienced a significant abnormal fluctuation in stock trading, with a cumulative closing price increase of over 100% from May 15 to May 28, 2025, indicating a serious deviation from the company's fundamentals and a high risk of speculation [1] Summary by Relevant Sections - Stock Trading Abnormality - The company's stock price has shown a substantial increase over a short period, leading to a classification of severe abnormal trading fluctuations [1] - Financial Performance - In the first quarter of 2025, the company reported a loss, highlighting a disconnect between stock performance and financial fundamentals [1] - Investor Advisory - The company has issued a special reminder for investors to be cautious, make rational decisions, and invest prudently due to the high speculation risk associated with the stock [1]

A股永安药业触及涨停录得11天7板，成交额12.13亿元。 订阅A股涨停捉妖队 +订阅 ...

这几只票暗盘资金正在偷偷流入，立即查看>> 永安药业（002365）触及涨停录得11天7板，成交额12.13亿元。 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要风险提示： 1、潜江永安药业股份有限公司（以下简称"公司"，证券简称：永安药业， 证券代码：002365）股票交易价格于 2025 年 5 月 23 日、2025 年 5 月 26 日、2025 年 5 月 27 日连续三个交易日内日收盘价格涨幅偏离值累计超出 20%，根据深圳 证券交易所的有关规定，属于股票交易异常波动的情况。公司股价短期涨幅较大， 敬请广大投资者理性投资，注意投资风险。 证券代码：002365 证券简称：永安药业 公告编号：2025-36 潜江永安药业股份有限公司 关于股票交易异常波动暨风险提示公告 针对公司股票交易异常波动，公司董事会对公司相关事项进行了核实，现 就有关情况说明如下： （一）经核查，公司前期披露的信息不存在需要更正、补充之处。 2、公司于 2025 年 5 月 6 日披露了《关于公司实际控制人、董事长被留置的 公告》（公告编号：2025-31），截至本公告披露日，公司暂未知悉上述事项的 进展及结论，公司将持续关注该事项后续进展情况，并根据相关规定及时履行信 息披露义务。 ...

Core Viewpoint - The pharmaceutical sector in A-shares has shown significant performance in 2025, with many stocks experiencing substantial price increases, despite a recent pullback in the market [1][2]. Group 1: Market Performance - As of May 26, the A-share market saw the Shanghai Composite Index drop by 0.05% to 3346.84 points, with the Shenzhen Component Index down 0.41% and the ChiNext Index down 0.8% [1]. - The biopharmaceutical sector has had a strong year, with five stocks rising over 100% and 35 stocks increasing by more than 50% since the beginning of 2025 [1][2]. Group 2: Individual Stock Performance - Notable performers include Yong'an Pharmaceutical, which has seen a price increase of 171.34%, and other companies like Yipin Pharmaceutical and Sanofi National Health, with increases of 169.87% and 138.47%, respectively [3][4]. - The Wind data indicates that the Wande Innovation Drug Index and the Pharmaceutical and Biological Index have risen by 11.21% and 3.17%, respectively, outperforming major indices like the Shanghai Composite and CSI 300 [2]. Group 3: Factors Driving Stock Prices - Yong'an Pharmaceutical's stock price surge is attributed to rising international prices of taurine and strong sales performance of its functional beverage brand "Yijianeng" on e-commerce platforms [5]. - The recent authorization deal between Sanofi Pharmaceutical and Pfizer for a breakthrough PD-1/VEGF bispecific antibody has also driven stock prices, with potential total transaction value exceeding $6 billion [9]. - The acceleration of innovative drug development and the increasing focus on AI in healthcare are contributing factors to the rising stock prices of several pharmaceutical companies [10]. Group 4: Future Outlook - Analysts are optimistic about the investment opportunities in innovative drugs for the second half of 2025, citing the international competitiveness of China's innovative drug development [12]. - The pharmaceutical industry is expected to benefit from ongoing innovation, demographic trends, and favorable policy environments, with a focus on innovative drugs and consumer recovery [12].